tab008
Efficacy
BioDlink Biopharm Co., Ltd.Phase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 81/ 100
Competitive context
24 Active assets in the Efficacy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Metformin Xijing Hospital | Phase 4 | BB |
DEXAMETHASONE Shandong Provincial Hospital | Phase 4 | BB |
Pioglitazone Xijing Hospital | Phase 4 | B |
Sodium Oligomannate First Affiliated Hospital Xi'an Jiaotong University | Phase 4 | B |
gv-971 First Affiliated Hospital Xi'an Jiaotong University | Phase 4 | B |
View all 37 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →